Table 2. Efficacy According to RECIST, Version 1.1.
| Efficacy parameters | Arm A: pazopanib/gemcitabine (n = 43) | Arm B: pazopanib (n = 43) | HR (95% CI) | P value |
|---|---|---|---|---|
| PFS rate at 12 wk, % | 74 | 47 | NA | .01 |
| PFS, mo | 5.6 | 2.0 | 0.58 (0.36-0.92) | .02 |
| TTP, mo | 5.6 | 2.0 | 0.57 (0.36-0.91) | .02 |
| OS, mo | 13.1 | 11.2 | 0.98 (0.60-1.58) | .83 |
| ORR (CR/PR), No. (%) | 5 (11) | 2 (5) | ||
| CR | 1 (2) | 0 | NA | .10 |
| PR | 4 (9) | 2 (5) | ||
| SD | 27 (63) | 20 (47) |
Abbreviations: CR, complete response; HR, hazard ratio; NA, not applicable; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease; TTP, time to progression.